newsfilter
← Latest News
Business Wire·

SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that Eddie